Vascular inflammation is a stronger predictor of residual cardiovascular risk than LDL cholesterol level among statin-treated patients. This finding from a large analysis of contemporary trials points to a potential new standard of care for atherosclerosis.
Dietary Supplements Don’t Stack Up to Low-Dose Statin Therapy for LDL-C Reduction
Despite marketing claims, none of six dietary supplements commonly used for lipid lowering significantly reduced LDL cholesterol versus placebo adults with elevated atherosclerotic risk, a new study finds.
Genetic Analysis of Evacetrapib Outcomes Fails to Confirm Findings with Dalcetrapib
A genotype found to be associated with reduced cardiovascular events in a study of dalcetrapib wasn’t associated with benefit in a trial of fellow CETP inhibitor evacetrapib.
Cleveland Clinic’s Stanley Hazen, MD, PhD, Named a 2017 AHA Distinguished Scientist
The physician-scientist draws the American Heart Association’s highest scientific honor for decades of pioneering research in multiple areas.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
CANTOS: Why It’s a Big Deal — and 5 More Things to Know About It
The recent landmark trial conclusively proved the inflammatory hypothesis of atherothrombosis. But it did a good deal more. Dr. Steven Nissen explains.
Nonlethal Targeting of Gut Microbes Successfully Treats Atherosclerosis
The story linking gut microbes, TMAO and heart disease has turned toward therapy interventions with the first demonstrated targeting of a gut microbial pathway to curb diet-induced heart disease.